WallStreetZenWallStreetZen

NASDAQ: RARE
Ultragenyx Pharmaceutical Inc Stock Ownership - Who owns Ultragenyx Pharmaceutical?

OverviewForecastEarningsRevenueDividendOwnership

Insider buying vs selling

Have Ultragenyx Pharmaceutical Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Emil D. KakkisPresident CEO2024-12-3011,727$42.23
$495.23kSell
Emil D. KakkisPresident CEO2024-12-108,273$50.00
$413.65kSell
Howard HornChief Financial Officer2024-10-107,465$52.76
$393.85kSell
Theodore Alan HuizengaSVP Chief Accounting Officer2024-09-0391$56.19
$5.11kSell
Emil D. KakkisPresident CEO2024-09-0320,000$55.85
$1.12MSell
Emil D. KakkisPresident CEO2024-08-0620,000$50.17
$1.00MSell
Corazon Corsee D. SandersDirector2024-07-02584$40.98
$23.93kSell
Karah Herdman ParschauerEVP and Chief Legal Officer2024-06-129,806$45.00
$441.27kSell
Corazon Corsee D. SandersDirector2024-06-101,737$41.10
$71.39kSell
Eric CrombezEVP and Chief Medical Officer2024-05-02354$43.66
$15.46kSell

1 of 3

RARE insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when RARE insiders and whales buy or sell their stock.

RARE Shareholders

What type of owners hold Ultragenyx Pharmaceutical Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Vanguard Group Inc10.77%9,945,473$446.05MInstitution
Emil D. Kakkis7.84%7,236,560$324.56MInsider
Blackrock Inc 16.31%5,828,848$261.42MInstitution
Blackrock Inc6.31%5,828,848$261.42MInstitution
Sands Capital Management LLC5.54%5,118,255$229.55MInstitution
Fmr LLC5.11%4,718,234$211.61MInsider
Wellington Management Group LLP4.51%4,165,424$186.82MInstitution
Price T Rowe Associates Inc3.32%3,068,654$137.63MInstitution
Alkeon Capital Management LLC3.26%3,011,716$135.08MInstitution
State Street Corp2.88%2,664,077$119.48MInstitution

1 of 3

RARE vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
RARE84.48%15.52%Net SellingNet Selling
SRRK56.37%43.63%Net SellingNet Selling
BHVN81.64%18.36%Net BuyingNet Buying
VKTX74.05%9.01%Net SellingNet Selling
ADMA78.83%21.17%Net SellingNet Selling
View Top Biotech Stocks

Ultragenyx Pharmaceutical Stock Ownership FAQ

Who owns Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical (NASDAQ: RARE) is owned by 93.07% institutional shareholders, 17.10% Ultragenyx Pharmaceutical insiders, and 0.00% retail investors. Emil D. Kakkis is the largest individual Ultragenyx Pharmaceutical shareholder, owning 7.24M shares representing 7.84% of the company. Emil D. Kakkis's Ultragenyx Pharmaceutical shares are currently valued at $318.77M.

If you're new to stock investing, here's how to buy Ultragenyx Pharmaceutical stock.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.